Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0001 USD
Change Today 0.00 / 0.00%
Volume 0.0
SPPH On Other Exchanges
As of 4:30 PM 05/7/15 All times are local (Market data is delayed by at least 15 minutes).

spencer pharmaceutical inc (SPPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

spencer pharmaceutical inc (SPPH) Related Businessweek News

No Related Businessweek News Found

spencer pharmaceutical inc (SPPH) Details

Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America and Europe. The company was incorporated in 1998 and is based in Boston, Massachusetts.

Founded in 1998

spencer pharmaceutical inc (SPPH) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

spencer pharmaceutical inc (SPPH) Key Developments

District Court Orders Spencer Penalty of $150,000

Canadian stock promoter Jean-Francois Amyot, two companies he controlled and Spencer Pharmaceutical Inc. were ordered to pay $7 million over charges by the Securities and Exchange Commission that they orchestrated a fake buyout offer that more than doubled the price of Spencer's stock. In 2010, Spencer issued press releases claiming it had received an unsolicited $245 million buyout offer from a Kuwait-based company it didn't identify. But no such offer existed, the SEC said in its lawsuit filed in U.S. District Court in Boston in 2012. Spencer was controlled by Amyot, the commission claimed. He allegedly worked with Spencer CEO Maximilien Arella, executive vice president Ian Morrice and two consulting firms Amyot controlled, IAB Media Inc. and Hilbroy Advisory Inc., to create and distribute the press releases. Amyot made more than $5 million off the pump-and-dump scheme, the SEC claimed. The district court ordered Sept. 30, that Amyot not serve as a director or officer of a public company or participate in penny stock offerings. Amyot, Hillbroy and IAB must return $5.88 million and pay $1.05 million in interest. Spencer must pay a penalty of $150,000. The court also fined Amyot $5,425 for failing to appear at the trial without notifying the SEC or court.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPPH:US $0.00 USD 0.00

SPPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SPPH.
View Industry Companies

Industry Analysis


Industry Average

Valuation SPPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SPENCER PHARMACEUTICAL INC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at